Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Fortress Biotech Inc

Current price
2.17 USD +0.1 USD (+4.83%)
Last closed 1.98 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 32 621 160 USD
Yield for 12 month +233.18 %
21.11.2021 - 28.11.2021

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida. Address: 1111 Kane Concourse, Bay Harbor Islands, FL, United States, 33154


WallStreet Target Price

44.6 USD

P/E ratio

Dividend Yield

Current Year

+75 743 000 USD

Last Year

+68 791 000 USD

Current Quarter

+34 752 000 USD

Last Quarter

+17 386 000 USD

Current Year

+44 968 000 USD

Last Year

+36 707 000 USD

Current Quarter

+28 323 000 USD

Last Quarter

+9 619 000 USD

Key Figures FBIO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -186 364 000 USD
Operating Margin TTM -207.96 %
PE Ratio
Return On Assets TTM -50.94 %
PEG Ratio -0.1
Return On Equity TTM -414.52 %
Wall Street Target Price 44.6 USD
Revenue TTM 61 971 000 USD
Book Value 1.87 USD
Revenue Per Share TTM 8.94 USD
Dividend Share
Quarterly Revenue Growth YOY -4.7 %
Dividend Yield
Gross Profit TTM -85 658 000 USD
Earnings Share -11.34 USD
Diluted Eps TTM -11.34 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin -126.36 %

Dividend Analytics FBIO

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History FBIO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:15
Payout Ratio
Last Split Date 10.10.2023
Dividend Date

Stock Valuation FBIO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 0.0128
Price Sales TTM 0.8248
Enterprise Value EBITDA 0.0737
Price Book MRQ 1.0999

Financials FBIO

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators FBIO

For 52 weeks

1.24 USD 17.4 USD
50 Day MA 3.03 USD
Shares Short Prior Month 91 614
200 Day MA 7.72 USD
Short Ratio 2.22
Shares Short 169 877
Short Percent 2.55 %